LivaNova

LIVN

Market cap $2.88B

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To liste.

LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis. The Company will present a five-year analysis of the THN-3 randomized control trial (RCT), which studied the use of its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). LivaNova will also deliver an oral presentation and feature a scientif.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LivaNova PLC (NASDAQ:LIVN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Financial Officer Briana Gotlin - VP, IR Conference Call Participants Neha Begwani - Morgan Stanley Presentation Neha Begwani Managing Director Well thank you all for joining today. My name is Neha Begwani, and I'm part of our medtech investment banking coverage team.

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board. “LivaNova is pleased to welcome Don to our Board of Directors,” said William Kozy, Chair of the Board. “Over the course of 30 years, he has amassed expertise in finance, accounting, and strategy, much of which he honed while s.

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during fireside chats at the two following September healthcare conferences in New York City: Baird 2025 Global Healthcare Conference on Tues., Sept. 9, from 3:45-4:15 p.m. EDT Morgan Stanley 23rd Annual Global Healthcare Conference on Wed., Sept.

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusion System in China, the second-largest market for LivaNova heart-lung machines (HLMs) after the United States. The Essenz Perfusion System, which recently received regulatory approval from China's National Medical Products Administration (NMPA), enables a patient-tailored perfusion approach rooted in data-driven decision-maki.

LivaNova PLC (NASDAQ:LIVN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Briana Gotlin - Vice President of Investor Relations Stephanie Bolton - President of Global Epilepsy Vladimir A. Makatsaria - CEO & Director Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division David Kenneth Rescott - Robert W.